RT Journal Article
SR Electronic
T1 Contributions of Different Modes of TRPV1 Activation to TRPV1 Antagonist-Induced Hyperthermia
JF The Journal of Neuroscience
JO J. Neurosci.
FD Society for Neuroscience
SP 1435
OP 1440
DO 10.1523/JNEUROSCI.5150-09.2010
VO 30
IS 4
A1 Garami, Andras
A1 Shimansky, Yury P.
A1 Pakai, Eszter
A1 Oliveira, Daniela L.
A1 Gavva, Narender R.
A1 Romanovsky, Andrej A.
YR 2010
UL http://www.jneurosci.org/content/30/4/1435.abstract
AB Transient receptor potential vanilloid-1 (TRPV1) antagonists are widely viewed as next-generation pain therapeutics. However, these compounds cause hyperthermia, a serious side effect. TRPV1 antagonists differentially block three modes of TRPV1 activation: by heat, protons, and chemical ligands (e.g., capsaicin). We asked what combination of potencies in these three modes of TRPV1 activation corresponds to the lowest potency of a TRPV1 antagonist to cause hyperthermia. We studied hyperthermic responses of rats, mice, and guinea pigs to eight TRPV1 antagonists with different pharmacological profiles and used mathematical modeling to find a relative contribution of the blockade of each activation mode to the development of hyperthermia. We found that the hyperthermic effect has the highest sensitivity to the extent of TRPV1 blockade in the proton mode (0.43 to 0.65) with no to moderate sensitivity in the capsaicin mode (−0.01 to 0.34) and no sensitivity in the heat mode (0.00 to 0.01). We conclude that hyperthermia-free TRPV1 antagonists do not block TRPV1 activation by protons, even if they are potent blockers of the heat mode, and that decreasing the potency to block the capsaicin mode may further decrease the potency to cause hyperthermia.